198 related articles for article (PubMed ID: 19496746)
1. Dry powder nasal vaccines as an alternative to needle-based delivery.
Hickey AJ; Garmise RJ
Crit Rev Ther Drug Carrier Syst; 2009; 26(1):1-27. PubMed ID: 19496746
[TBL] [Abstract][Full Text] [Related]
2. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
3. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
Wang SH; Thompson AL; Hickey AJ; Staats HF
Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
[TBL] [Abstract][Full Text] [Related]
4. Insoluble powder formulation as an effective nasal drug delivery system.
Ishikawa F; Murano M; Hiraishi M; Yamaguchi T; Tamai I; Tsuji A
Pharm Res; 2002 Aug; 19(8):1097-104. PubMed ID: 12240934
[TBL] [Abstract][Full Text] [Related]
5. Nasal route for vaccine and drug delivery: Features and current opportunities.
Lobaina Mato Y
Int J Pharm; 2019 Dec; 572():118813. PubMed ID: 31678521
[TBL] [Abstract][Full Text] [Related]
6. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
7. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice.
Scherließ R; Mönckedieck M; Young K; Trows S; Buske S; Hook S
Int J Pharm; 2015 Feb; 479(2):408-15. PubMed ID: 25595389
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders.
Yu YS; AboulFotouh K; Xu H; Williams G; Suman J; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2023 Jun; 640():122990. PubMed ID: 37127138
[TBL] [Abstract][Full Text] [Related]
9. Nasal vaccine innovation.
Jabbal-Gill I
J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.
Thakkar SG; Warnken ZN; Alzhrani RF; Valdes SA; Aldayel AM; Xu H; Williams RO; Cui Z
J Control Release; 2018 Dec; 292():111-118. PubMed ID: 30339906
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.
Ambrus R; Gieszinger P; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P; Bartos C
Molecules; 2020 Feb; 25(5):. PubMed ID: 32120992
[TBL] [Abstract][Full Text] [Related]
12. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump.
Djupesland PG; Skretting A
J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):280-9. PubMed ID: 22251061
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with dry powder vaccines.
Bahamondez-Canas TF; Cui Z
Eur J Pharm Biopharm; 2018 Jan; 122():167-175. PubMed ID: 29122735
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery.
Alpar HO; Somavarapu S; Atuah KN; Bramwell VW
Adv Drug Deliv Rev; 2005 Jan; 57(3):411-30. PubMed ID: 15560949
[TBL] [Abstract][Full Text] [Related]
15. Characterizing regional drug delivery within the nasal airways.
Chen J; Finlay WH; Vehring R; Martin AR
Expert Opin Drug Deliv; 2024 Apr; 21(4):537-551. PubMed ID: 38568159
[TBL] [Abstract][Full Text] [Related]
16. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery.
Salatin S; Barar J; Barzegar-Jalali M; Adibkia K; Milani MA; Jelvehgari M
Arch Pharm Res; 2016 Sep; 39(9):1181-92. PubMed ID: 27352214
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys.
Torikai Y; Sasaki Y; Sasaki K; Kyuno A; Haruta S; Tanimoto A
J Pharm Sci; 2021 May; 110(5):2038-2046. PubMed ID: 33278410
[TBL] [Abstract][Full Text] [Related]
18. Improved nasal bioavailability of elcatonin by insoluble powder formulation.
Ishikawa F; Katsura M; Tamai I; Tsuji A
Int J Pharm; 2001 Aug; 224(1-2):105-14. PubMed ID: 11472819
[TBL] [Abstract][Full Text] [Related]
19. The Enhancement of Nasal Drug Absorption From Powder Formulations by the Addition of Sodium Carboxymethyl Cellulose.
Tanaka A; Furubayashi T; Yamasaki H; Takano K; Kawakami M; Kimura S; Inoue D; Katsumi H; Sakane T; Yamamoto A
IEEE Trans Nanobioscience; 2016 Dec; 15(8):798-803. PubMed ID: 28060709
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery.
Alshweiat A; Ambrus R; Csoka I
Curr Med Chem; 2019; 26(35):6459-6492. PubMed ID: 31453778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
